On the stock market since 1997, it operates in the world of health and science. It has 11,000 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 12% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 30% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 13% a year on average.
The company sells $2.0B a year; the problem isn’t sales — it’s costs running above that number.
The average analyst price target is $78.00 — 29% above today’s price.
A loss of $18.7M against $2.0B in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 10/100.
The growth engine is running at low revs right now. Report-card grade: 48/100.
On our five-subject report card, RDNT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: RDNT has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (60/100) says the stock isn’t cheap.